Walter Gulisano

Walter Gulisano

Auto-generated profile, based on publicly available information

Walter Gulisano

University of Catania, Catania Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
WGWalter Gulisano
Walter Gulisano
DMDaniele Maugeri
Daniele Maugeri
MBMarian A Baltrons
Marian A Baltrons
MFMauro Fà
Mauro Fà
AAArianna Amato
Arianna Amato
OAOttavio Arancio
Ottavio Arancio
The “Amyloid Cascade Hypothesis” has dominated the Alzheimer’s disease (AD) field in the last 25 years. It posits that the increase of amyloid-β (Aβ) is the key event in AD that triggers tau pathology followed by neuronal death and eventually, the di

20 January 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MFM. Fá
M. Fá
Daniela PuzzoDaniela Puzzo
Daniela Puzzo
RPRoberto Piacentini
Roberto Piacentini
ASA. Staniszewski
A. Staniszewski
HZH. Zhang
H. Zhang
OAO. Arancio
O. Arancio
Non-fibrillar soluble oligomeric forms of amyloid-β peptide (oAβ) and tau proteins are likely to play a major role in Alzheimer’s disease (AD). The prevailing hypothesis on the disease etiopathogenesis is that oAβ initiates tau pathology that slowly spreads throughout the medial temporal cortex and neocortices independently of Aβ, eventually leading to memory loss. Here we show that a brief exposure to extracellular recombinant human tau oligomers (oTau), but not monomers, produces an impairment of long-term potentiation (LTP) and memory, independent of the presence of high oAβ levels. The impairment is immediate as it raises as soon as 20 min after exposure to the oligomers. These effects are reproduced either by oTau extracted from AD human specimens, or naturally produced in mice overexpressing human tau. Finally, we found that oTau could also act in combination with oAβ to produce these effects, as sub-toxic doses of the two peptides combined lead to LTP and memory impairment. These findings provide a novel view of the effects of tau and Aβ on memory loss, offering new therapeutic opportunities in the therapy of AD and other neurodegenerative diseases associated with Aβ and tau pathology.

30 April 2015 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
Daniela PuzzoDaniela Puzzo
Daniela Puzzo
WGWalter Gulisano
Walter Gulisano
APAgostino Palmeri
Agostino Palmeri
OAOttavio Arancio
Ottavio Arancio
Introduction: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss and personality changes, leading to dementia. Histopathological hallmarks are represented by aggr...

11 July 2017 in eLife
Verified
Journal Article
Open access
Daniela PuzzoDaniela Puzzo
Daniela Puzzo
RPRoberto Piacentini
Roberto Piacentini
MFMauro Fá
Mauro Fá
WGWalter Gulisano
Walter Gulisano
DPDomenica D Li Puma
Domenica D Li Puma
OAOttavio Arancio
Ottavio Arancio
The concurrent application of subtoxic doses of soluble oligomeric forms of human amyloid-beta (oAβ) and Tau (oTau) proteins impairs memory and its electrophysiological surrogate long-term potentiation (LTP), effects that may be mediated by intra-neuronal oligomers uptake. Intrigued by these findings, we investigated whether oAβ and oTau share a common mechanism when they impair memory and LTP in mice. We found that as already shown for oAβ, also oTau can bind to amyloid precursor protein (APP). Moreover, efficient intra-neuronal uptake of oAβ and oTau requires expression of APP. Finally, the toxic effect of both extracellular oAβ and oTau on memory and LTP is dependent upon APP since APP-KO mice were resistant to oAβ- and oTau-induced defects in spatial/associative memory and LTP. Thus, APP might serve as a common therapeutic target against Alzheimer's Disease (AD) and a host of other neurodegenerative diseases characterized by abnormal levels of Aβ and/or Tau.

10 June 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FCFilippo Caraci
Filippo Caraci
WGWalter Gulisano
Walter Gulisano
CGChiara A. Guida
Chiara A. Guida
AIAgata A. R. Impellizzeri
Agata A. R. Impellizzeri
Filippo DragoFilippo Drago
Filippo Drago
APAgostino Palmeri
Agostino Palmeri
Transforming Growth Factor β1 (TGF-β1) is a well-known neuroprotective and neurotrophic factor demonstrated to play a role in synaptic transmission. However, its involvement in physiological mechanisms underlying synaptic plasticity and memory at hippocampal level has not been thoroughly investigated. Here, we examine the role of TGF-β1 in hippocampal long-term potentiation (LTP) and memory in adult wild type mice. Our data provide evidence that administration of exogenous TGF-β1 is able to convert early-phase-LTP into late-phase-LTP. Furthermore, we show that the block of the endogenous TGF-β1 signaling pathway by the specific TGF-β1 inhibitor SB431542, impairs LTP and object recognition memory. The latter impairment was rescued by administration of exogenous TGF-β1, suggesting that endogenously produced TGF-β1 plays a role in physiological mechanisms underlying LTP and memory. Finally, TGF-β1 functional effect correlates with an increased expression of the phosphorylated transcription factor cAMP-Responsive Element Binding protein.

1 October 2015 in Neuroscience
Verified
Journal Article
Closed access
Daniela PuzzoDaniela Puzzo
Daniela Puzzo
WGW. Gulisano
W. Gulisano
OAO. Arancio
O. Arancio
APAgostino Palmeri
Agostino Palmeri